Orsola Crespi, Isotta Giunipero di Corteranzo, Eleonora Bongiovanni, Umberto Santaniello, Michela Ortoncelli, Pietro Quaglino, Simone Ribero, Luca Mastorino
{"title":"Real-World Strategies for Biologic Dose Escalation and Reduction in Psoriasis and Psoriatic Arthritis: A Systematic Review.","authors":"Orsola Crespi, Isotta Giunipero di Corteranzo, Eleonora Bongiovanni, Umberto Santaniello, Michela Ortoncelli, Pietro Quaglino, Simone Ribero, Luca Mastorino","doi":"10.1177/12034754261484596","DOIUrl":"https://doi.org/10.1177/12034754261484596","url":null,"abstract":"<p><strong>Background: </strong>Biologic therapies have improved treatment of moderate-to-severe psoriasis and psoriatic arthritis. However, real-world dosing often deviates from standard protocols to address suboptimal responses, sustain long-term control, and manage safety or cost. Dose escalation (DE) and dose reduction (DR) strategies are widely used, but data on their frequency, rationale, and outcomes remain fragmented.</p><p><strong>Objective: </strong>To systematically review real-world evidence on DE and DR practices for biologic therapies in moderate-to-severe psoriasis and psoriatic arthritis, focusing on definitions, clinical criteria, and success rates.</p><p><strong>Methods: </strong>A systematic literature review was conducted using PubMed, Scopus, Embase, and the Cochrane Library from January 1, 2005, through December 31, 2024. Eligible studies included adults with moderate-to-severe plaque psoriasis or psoriatic arthritis receiving tumor necrosis factor inhibitors, interleukin-12 (IL-12)/IL-23 inhibitors, IL-17 inhibitors, or IL-23 inhibitors, with reported off-label dose modifications. Data on definitions, timing, clinical criteria, and outcomes were extracted and synthesized.</p><p><strong>Results: </strong>From 2623 records, 63 studies were included. Dose adjustments were defined using varied clinical or timing criteria. DE was most successful when applied moderately and promptly. DR was commonly implemented after stable remission and maintained disease control in 50% to 90% of patients. Adalimumab was the most frequently adjusted biologic. IL-17 and IL-23 inhibitors also showed flexibility. Inconsistent definitions and outcome reporting limited comparability across studies.</p><p><strong>Conclusion: </strong>Dose adjustments are common but inconsistently defined, highlighting the need for standardized definitions and clinical guidance.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484596"},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Raquel Lazarowitz, Santina Conte, Amina Moustaqim-Barrette, Samantha Balass, François Lagacé, Elena Netchiporouk, Ivan V Litvinov
{"title":"Sun Protection Behaviours and Melanoma Risk Perception in Canadian Jewish Populations: A Cross-Sectional Survey Study.","authors":"Raquel Lazarowitz, Santina Conte, Amina Moustaqim-Barrette, Samantha Balass, François Lagacé, Elena Netchiporouk, Ivan V Litvinov","doi":"10.1177/12034754261485274","DOIUrl":"https://doi.org/10.1177/12034754261485274","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261485274"},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Irene Rivera-Ruiz, Alberto Soto-Moreno, Miguel Mansilla-Polo, Patricia Garbayo-Salmons, Daniel Muñoz-Barba, César Guijarro-Sánchez, Alejandro Molina-Leyva
{"title":"Type 1 Diabetes is Associated With Increased Therapeutic Burden in Hidradenitis Suppurativa: A Multicenter Retrospective Matched Case-Control Study.","authors":"Irene Rivera-Ruiz, Alberto Soto-Moreno, Miguel Mansilla-Polo, Patricia Garbayo-Salmons, Daniel Muñoz-Barba, César Guijarro-Sánchez, Alejandro Molina-Leyva","doi":"10.1177/12034754261484189","DOIUrl":"https://doi.org/10.1177/12034754261484189","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with multiple systemic comorbidities. Although its association with type 2 diabetes is well established, the clinical impact of coexisting type 1 diabetes (T1D) remains poorly defined.</p><p><strong>Objectives: </strong>To compare the clinical characteristics, disease burden, and therapeutic requirements of patients with HS and T1D with matched HS controls.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective matched case-control study across 3 tertiary dermatology departments. Patients with HS and confirmed T1D were matched 1:3 by age, sex, and baseline Hurley stage. Clinical and therapeutic outcomes were assessed over a standardized 48 week follow-up.</p><p><strong>Results: </strong>Twelve patients with HS and T1D and 33 matched controls were included. Baseline disease severity was comparable. During follow-up, patients with HS + T1D had higher mean International Hidradenitis Suppurativa Severity Score System scores (11.95 vs 6.24; <i>P</i> = .01), more draining tunnels (11.0 vs 3.97; <i>P</i> < .01), received more systemic treatments (4.10 vs 3.06; <i>P</i> = .03), and underwent more surgical procedures (1.67 vs 0.67; <i>P</i> < .01).</p><p><strong>Conclusions: </strong>Patients with HS and coexisting T1D may experience a greater inflammatory and therapeutic burden than matched controls. These findings support closer multidisciplinary management and warrant prospective studies to validate T1D as a potential modifier of HS severity.</p><p><strong>Limitations: </strong>Retrospective design and small sample size.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484189"},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Craniofacial Angiosarcoma.","authors":"Heli Yang","doi":"10.1177/12034754261491228","DOIUrl":"https://doi.org/10.1177/12034754261491228","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261491228"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lupus Vulgaris of the Face.","authors":"Sushant Agrawal, Gomathy Sethuraman","doi":"10.1177/12034754261488370","DOIUrl":"https://doi.org/10.1177/12034754261488370","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261488370"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Blaschkoid Psoriasis.","authors":"Yang He, Chunming Li","doi":"10.1177/12034754261488358","DOIUrl":"https://doi.org/10.1177/12034754261488358","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261488358"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Proximal Onychomycosis.","authors":"Nuran C Golbasi, Shari R Lipner","doi":"10.1177/12034754261491230","DOIUrl":"https://doi.org/10.1177/12034754261491230","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261491230"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Silvia Borriello, Giovanni Cavaliere, Matteo Brizio, Sophie Frassy, Francois Rosset, Nadia Sciamarrelli, Paolo Borrelli, Federica Sardanelli, Astrid Lappi, Pietro Quaglino, Simone Ribero, Luca Mastorino
{"title":"Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study.","authors":"Silvia Borriello, Giovanni Cavaliere, Matteo Brizio, Sophie Frassy, Francois Rosset, Nadia Sciamarrelli, Paolo Borrelli, Federica Sardanelli, Astrid Lappi, Pietro Quaglino, Simone Ribero, Luca Mastorino","doi":"10.1177/12034754261484533","DOIUrl":"https://doi.org/10.1177/12034754261484533","url":null,"abstract":"<p><strong>Background: </strong>Omalizumab is a highly effective third-line treatment for chronic spontaneous urticaria (CSU) refractory to antihistamines. However, disease relapse upon cessation is a significant clinical challenge. Real-world evidence comparing different discontinuation strategies is scarce.</p><p><strong>Methods: </strong>This retrospective, multicenter, real-world study evaluated 199 patients with refractory CSU treated with omalizumab (300 mg/month) in the Piedmont-Aosta Valley region. We assessed effectiveness using Urticaria Activity Score (UAS/UAS7) and Dermatology Life Quality Index (DLQI). The primary outcomes were response rates, relapse rates after abrupt discontinuation versus gradual dose spacing, and predictors of these outcomes.</p><p><strong>Results: </strong>Omalizumab demonstrated high effectiveness, achieving a complete response rate of 71% after the first treatment cycle, with drastic reductions in mean UAS7 (from 28.8 to 4.3) and DLQI (from 25.3 to 0.8) by month 4. Abrupt discontinuation resulted in a high relapse rate of 73.7%, with a short median time to recurrence of 2 months. Multivariate analysis found no significant baseline predictors of response. Counterintuitively, a higher baseline UAS7 was associated with a lower risk of relapse. A subgroup of 48 patients, characterized as \"super-responders,\" underwent gradual dose spacing. This group achieved a significantly lower relapse rate of 27.1% after abrupt cessation, without significant symptomatic worsening during tapering.</p><p><strong>Conclusions: </strong>Omalizumab is an effective control therapy for CSU in a real-world setting. Abrupt discontinuation leads to rapid relapse in the majority of patients. Gradual dose spacing represents a promising strategy to prolong remission and reduce drug burden, particularly in patients exhibiting excellent initial therapeutic response.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484533"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andy Dongkwun Lee, Darshana Seeburruth, Samantha Bestavros, Ahmed Bagit, Siddhartha Sood, Edgar Akuffo-Addo, Marissa Joseph
{"title":"Biologic and Systemic Therapies in Pediatric Cutaneous Lupus Erythematosus: An Evidence-Based Review.","authors":"Andy Dongkwun Lee, Darshana Seeburruth, Samantha Bestavros, Ahmed Bagit, Siddhartha Sood, Edgar Akuffo-Addo, Marissa Joseph","doi":"10.1177/12034754261480642","DOIUrl":"https://doi.org/10.1177/12034754261480642","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261480642"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lepromatous Leprosy.","authors":"Akarsh Agrawal, Ankita Srivastava","doi":"10.1177/12034754261487452","DOIUrl":"https://doi.org/10.1177/12034754261487452","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261487452"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}